JP7235287B2 - 腸内消化に対する改善された安定性を有する抗体 - Google Patents

腸内消化に対する改善された安定性を有する抗体 Download PDF

Info

Publication number
JP7235287B2
JP7235287B2 JP2018536696A JP2018536696A JP7235287B2 JP 7235287 B2 JP7235287 B2 JP 7235287B2 JP 2018536696 A JP2018536696 A JP 2018536696A JP 2018536696 A JP2018536696 A JP 2018536696A JP 7235287 B2 JP7235287 B2 JP 7235287B2
Authority
JP
Japan
Prior art keywords
antibody
bovine
antibodies
igg1
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537117A (ja
JP2018537117A5 (enExample
Inventor
バートン，ランダル，エドワード
Original Assignee
サークル３３ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サークル３３ エルエルシー filed Critical サークル３３ エルエルシー
Publication of JP2018537117A publication Critical patent/JP2018537117A/ja
Publication of JP2018537117A5 publication Critical patent/JP2018537117A5/ja
Priority to JP2022156598A priority Critical patent/JP2022185053A/ja
Application granted granted Critical
Publication of JP7235287B2 publication Critical patent/JP7235287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018536696A 2015-10-05 2016-09-29 腸内消化に対する改善された安定性を有する抗体 Active JP7235287B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022156598A JP2022185053A (ja) 2015-10-05 2022-09-29 腸内消化に対する改善された安定性を有する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237270P 2015-10-05 2015-10-05
US62/237,270 2015-10-05
PCT/US2016/054304 WO2017062253A2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022156598A Division JP2022185053A (ja) 2015-10-05 2022-09-29 腸内消化に対する改善された安定性を有する抗体

Publications (3)

Publication Number Publication Date
JP2018537117A JP2018537117A (ja) 2018-12-20
JP2018537117A5 JP2018537117A5 (enExample) 2019-11-07
JP7235287B2 true JP7235287B2 (ja) 2023-03-08

Family

ID=58488349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018536696A Active JP7235287B2 (ja) 2015-10-05 2016-09-29 腸内消化に対する改善された安定性を有する抗体
JP2022156598A Pending JP2022185053A (ja) 2015-10-05 2022-09-29 腸内消化に対する改善された安定性を有する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022156598A Pending JP2022185053A (ja) 2015-10-05 2022-09-29 腸内消化に対する改善された安定性を有する抗体

Country Status (8)

Country Link
US (2) US11891440B2 (enExample)
EP (1) EP3359190A4 (enExample)
JP (2) JP7235287B2 (enExample)
AU (2) AU2016335912B2 (enExample)
BR (1) BR112018006953A2 (enExample)
CA (1) CA3039177A1 (enExample)
IL (1) IL258496A (enExample)
WO (1) WO2017062253A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790533B (zh) * 2016-08-15 2023-04-04 国立大学法人北海道大学 抗pd-l1抗体
WO2020123798A1 (en) * 2018-12-12 2020-06-18 President And Fellows Of Harvard College Bovine versions of fcmbl for the detection and treatment of bovine microbial infections
WO2022109313A1 (en) * 2020-11-20 2022-05-27 Zoetis Services Llc Bovine antibody variants
WO2025057225A1 (en) * 2023-09-14 2025-03-20 Invitrogen Bioservices India Private Limited Engineered antibodies and uses thereof
CN120209146A (zh) * 2025-03-31 2025-06-27 上海百英生物科技股份有限公司 一种包含非天然氨基酸修饰的Claudin 6抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508862A (ja) 2004-06-28 2008-03-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｆｃ−インターフェロン−β融合タンパク質
JP2014503202A (ja) 2010-12-08 2014-02-13 アッヴィ・インコーポレイテッド ＴＮＦ−α結合性タンパク質

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2244735A4 (en) * 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US8647626B2 (en) * 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
EA201290241A1 (ru) * 2009-10-29 2013-02-28 Янссен Байотек Инк. Изменение гликозилирования антител
RU2013129203A (ru) * 2010-12-27 2015-02-10 Джапан Хелт Сайенсес Фаундейшн Моноклональное антитело, распознающее белок l2 папилломавируса человека (впч), и способ определения титра впч-нейтрализующего антитела, использующий такое антитело
EP2739650A4 (en) * 2011-08-01 2015-04-01 Avaxia Biologics Inc SPECIFIC BOVINE POLYCLONAL ANTIBODY OF HUMAN TNF
CN115850489A (zh) * 2016-08-15 2023-03-28 国立大学法人北海道大学 抗pd-1抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508862A (ja) 2004-06-28 2008-03-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｆｃ−インターフェロン−β融合タンパク質
JP2014503202A (ja) 2010-12-08 2014-02-13 アッヴィ・インコーポレイテッド ＴＮＦ−α結合性タンパク質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bhol, K. C. et al.，AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease，Inflamm. Bowel Dis.，2013年，Vol. 19(11)，pp. 2273-2281
Knight, K. L. et al.，Genetic engineering of bovine Ig. Construction and characterization of hapten-binding bovine/murine chimeric IgE, IgA, IgG1, IgG2, and IgG3 molecules，J. Immunol.，1988年，Vol. 140(10)，pp. 3654-3659
山本静雄 ほか，初乳抗体の腸管内での作用に関する研究，麻布大学雑誌，2008年，Vol. 17,18，pp. 202-210

Also Published As

Publication number Publication date
WO2017062253A3 (en) 2017-05-11
WO2017062253A2 (en) 2017-04-13
BR112018006953A2 (pt) 2018-10-23
CA3039177A1 (en) 2017-04-13
AU2023216791A1 (en) 2023-09-07
JP2018537117A (ja) 2018-12-20
US20220073602A1 (en) 2022-03-10
EP3359190A4 (en) 2020-05-06
IL258496A (en) 2018-05-31
US11891440B2 (en) 2024-02-06
AU2016335912B2 (en) 2023-08-31
JP2022185053A (ja) 2022-12-13
US20240067715A1 (en) 2024-02-29
AU2016335912A1 (en) 2018-05-24
EP3359190A2 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
JP2022185053A (ja) 腸内消化に対する改善された安定性を有する抗体
ES2755181T3 (es) Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
TW201800419A (zh) Ｌａｇ－３抗體、其抗原結合片段及其醫藥用途
JP6671069B2 (ja) 炎症性疾患の予防又は治療剤
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
TW201837056A (zh) Ｂ７－ｈ３抗體、其抗原結合片段及其醫藥用途
TW201010725A (en) Anti-IL-12/IL-23 antibodies
CN116490210A (zh) Cd70抗体及其应用
KR20140108520A (ko) CD1d에 대한 항체
JP2021519088A (ja) 抗ｃｄ２７抗体、その抗原結合フラグメント及びその医学的使用
WO2022242703A1 (zh) 抗msln抗体及其应用
CN113906053B (zh) 抗cea抗体及其应用
TW201900213A (zh) 免疫球蛋白ａ陽性細胞的調節
US20220396615A1 (en) Anti-human il6 monoclonal antibodies, preparation method therefor and use thereof
US20250346673A1 (en) Anti-bdca2 antibody and use thereof
CN118240081A (zh) 重组抗人ilt7抗体及其应用
CN115038497A (zh) TGF-β-RII结合蛋白质
WO2022103871A1 (en) Therapeutic compositions for the treatment of covid-19
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
WO2023103788A1 (zh) 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
CN112867785A (zh) 通过抗体介导的特定肠道细菌的中和作用治疗免疫性疾病

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220929

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221128

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230216

R150 Certificate of patent or registration of utility model

Ref document number: 7235287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150